Medicine

W-W Chen, L. Li, G. Yang, K. Li, Xiaoya Qi, W. Zhu, Y. Tang, H. Liu, G. Boden

2007.10.9EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

DOI: 10.1055/s-2007-985148

tlooto Summary

A potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM is suggested, and multiple regression analysis showed that FBG, plasma insulin and HOMA (IS) were independent influencing plasma F GF-21 levels.

Abstract

Fibroplast growth factor (FGF-21) is a recently discovered metabolic regulator. Its pathophysiologic role in humans remains unknown. In this study, we have investigated whether or not plasma FGF-21 level was different in patients with type 2 diabetes mellitus (T2DM) and non-diabetic controls. We also assessed associations between plasma FGF-21 body composition and several metabolic parameters. Fasting FGF-21 levels were significantly increased in patients with T2DM compared with controls (1.82+/-0.65 VS. 1.53+/-0.60 microg/L, P<0.05). In T2DM patients, fasting plasma FGF-21 correlate negatively with fasting blood glucose ( R= -0.31, P<0.05). Multiple regression analysis showed that FBG, plasma insulin and HOMA (IS) were independent influencing plasma FGF-21 levels. The present work suggests a potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM.

Citation format

CHEN, W-W, et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 116 1: 65–8.